A Real-World Study on Extranodal Lymphoma
1 other identifier
observational
5,000
0 countries
N/A
Brief Summary
The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2024
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 8, 2024
CompletedFirst Posted
Study publicly available on registry
August 27, 2024
CompletedStudy Start
First participant enrolled
September 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 1, 2029
August 27, 2024
August 1, 2024
3 years
August 8, 2024
August 23, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Progression Free Survival (PFS)
Progression-Free Survival (PFS) will be defined from the date of starting therapy and the date of disease progression, relapse or death from any cause.
Baseline up to data cut-off (up to approximately 1 year)
Secondary Outcomes (1)
Overall Survival (OS)
Baseline up to data cut-off (up to approximately 1 year)
Interventions
No interventions need to be specified for this study
Eligibility Criteria
Adult patients with histologically confirmed diagnosis of non-Hodgkin lymphoma with extranodal involvement.
You may qualify if:
- Age ≥ 18 years (including 18 years old).
- Patients newly diagnosed with non-Hodgkin lymphoma with extranodal involvement, whether it is primary, secondary, or cannot be determined.
- Patients who have received systematic clinical treatment.
- Patients with measurable lesions, at least containing one effective evaluation of efficacy.
You may not qualify if:
- Patients who only receive supportive treatment.
- Patients who cannot obtain effective evaluation data of efficacy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ruijin Hospitallead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- First Deputy Director, Hematology Department
Study Record Dates
First Submitted
August 8, 2024
First Posted
August 27, 2024
Study Start
September 1, 2024
Primary Completion (Estimated)
September 1, 2027
Study Completion (Estimated)
September 1, 2029
Last Updated
August 27, 2024
Record last verified: 2024-08